Vicuron Pharmaceuticals, Inc - Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported):

August 10, 2004

 


 

Vicuron Pharmaceuticals Inc.

(Exact Name of Registrant As Specified in its Charter)

 


 

 

Delaware   000-31145   04-3278032

(State or Other Jurisdiction

of Incorporation)

  (Commission File Number)  

(I.R.S. Employer

Identification Number)

 

455 South Gulph Road, Suite 305, King of Prussia, PA 19406

(Address of Principal Executive Offices) (Zip Code)

 

(610) 205-2300

(Registrant’s telephone number, including area code)

 

not applicable

(Former Name or Former Address, if Changed Since Last Report.)

 



Item 5. Other Events and Required FD Disclosure.

 

On August 10, 2004, Oscient Pharmaceuticals Corporation issued a press release announcing that it recently completed a Phase II trial of Ramoplanin for the treatment of Clostridium difficile-associated diarrhea (CDAD).


SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

   

VICURON PHARMACEUTICALS INC.

   

                    (Registrant)

Date: August 11, 2004

 

By:

 

/s/ George F. Horner III


       

George F. Horner III

       

President and Chief Executive Officer